KEY IDEA: It’s become easier to simply purchase a rival drug maker than to pour money into R&D. However, pharma’s worst enemy is its own culture which stymies innovation and rewards sales people who put numbers ahead of patients. Continue reading
KEY TAKEAWAY: How do you plan a strategy for 2017 when there are so any changes coming to health care? Rather than having a weeks worth of meetings to discuss the business and political climate there are some things that DTC marketers can do to prepare for 2017. Here are some ideas that might help.
KEY TAKEAWAY: If pharma CEO’s are celebrating the election of Donald Trump they are making a huge mistake. Now is the time to start looking forward to prepare the organization for changes that have to be implemented in order for pharma companies to thrive and survive. Old thinking and strategies are only good for CEO’s who want to maximize their compensation before bailing out. Continue reading
KEY TAKEAWAY: In talking to clients from over 15 pharma/biotech companies we predict that 2017 DTC spending will be flat or down when adjusted for increased costs. Companies will continue to experiment with digital but the disconnect between spending and ROI will hamper efforts. Continue reading
KEY TAKEAWAY: Developing a “me too” drug may be a waste of resources as insurers are only allowing one drug, in certain categories, on formularies. A strategy of “taking a slice of the pie” is shortsighted and fails to acknowledge the realities of today’s marketplace. Continue reading
KEY TAKEAWAY: More pharma companies are outsourcing R&D including clinical trials to reduce costs and better manage new drugs in the pipeline. However, there are risks involved which in turn could lead to higher development costs. Continue reading
KEY TAKEAWAY: Prescription drug prices jumped 38 percent in the last 10 years, compared to an 18 percent increase in general inflation, according to the Bureau of Labor Statistics. It’s time to let Medicare negotiate prescription drug prices like Canada and Britain, which do negotiate with drug makers. Continue reading